Aarti Pharmalabs Ltd.

NSE: AARTIPHARM | BSE: 543748 | ISIN: INE0LRU01027 | Industry: Pharmaceuticals
| Slowing Down Stock
608.8500 -30.15 (-4.72%)
NSE Mar 27, 2026 15:31 PM
Volume: 397.0K
 

608.85
-4.72%
ICICI Direct
Q3FY26 Sequential improvement driven by CDMO despite postponement of one shipment Revenues for the quarter improved 3.3% QoQ to 432.3 crore. EBITDA for the quarter grew by 36.9% QoQ to 102.3 crore and margins to 23.7% mainly driven by 1020 bps QoQ improvement in GPM to 60.1%. PAT for the quarter stood at 48 crore. The growth was subdued in Xanthine and API/ Intermediates segments which reported almost flat numbers sequentially 208 crore and 165 crore respectively. The CDMO segment reported 30% growth QoQ to 53 crore on lower base...
Aarti Pharmalabs Ltd. is trading below all available SMAs
More from Aarti Pharmalabs Ltd.
Recommended